ANNX · Program file
vonaprument
When did Annexon, Inc. say vonaprument results would come?
On , Annexon, Inc. wrote in its SEC Form 10-Q: “The Month 15 primary endpoint remains on track for the fourth quarter of 2026.” (Source)
Days left in the window the company stated: 73 · company’s wording: “fourth quarter of 2026”
Last checked: .
Watch this program: confirm your email to start one daily alert digest.
Program file
- Name as filed
- vonaprument
- Other names in filings
- ANX007
- Indication in the filing
- geographic atrophy (GA)
- Trials named in the same filing
- None listed
- Latest timing wording
- “The Month 15 primary endpoint remains on track for the fourth quarter of 2026.”
- Source
- 10-Q · filed · SEC accepted · accession 0001193125-26-346779 · SEC original
- Last checked
Program ANNX-vonaprument.